Published in Mol Pharmacol on August 12, 2004
Assessing the nature of lipid raft membranes. PLoS Comput Biol (2007) 1.26
Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J (2007) 1.00
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One (2013) 0.98
Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression? Neurosci Biobehav Rev (2009) 0.97
Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc Natl Acad Sci U S A (2005) 0.92
Pluronics and MDR reversal: an update. Mol Pharm (2014) 0.91
ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst (2014) 0.91
Extensive sphingolipid depletion does not affect lipid raft integrity or lipid raft localization and efflux function of the ABC transporter MRP1. Biochem J (2010) 0.90
ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients. Haematologica (2011) 0.88
Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. Mol Pharm (2012) 0.86
The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells. Br J Pharmacol (2012) 0.85
Bile salt-stimulated phospholipid efflux mediated by ABCB4 localized in nonraft membranes. J Lipid Res (2013) 0.83
Lipid rafts: dream or reality for cholesterol transporters? Eur Biophys J (2007) 0.79
Identification of P-glycoprotein co-fractionating proteins and specific binding partners in rat brain microvessels. J Neurochem (2015) 0.79
Sustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane Lipids. Langmuir (2015) 0.77
ATP-binding cassette transporter G2 activity in the bovine spermatozoa is modulated along the epididymal duct and at ejaculation. Biol Reprod (2012) 0.76
Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.76
Astrocyte-mediated regulation of multidrug resistance p-glycoprotein in fetal and neonatal brain endothelial cells: age-dependent effects. Physiol Rep (2016) 0.75
Identification of Novel Raft Marker Protein, FlotP in Bacillus anthracis. Front Microbiol (2016) 0.75
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther (2005) 1.82
Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther (2003) 1.78
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol (2005) 1.52
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol (2009) 1.49
Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther (2003) 1.39
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther (2006) 1.30
Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother (2007) 1.27
Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol (2007) 1.26
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit (2011) 1.24
Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract (2010) 1.16
Successful strategy to improve the specificity of electronic statin-drug interaction alerts. Eur J Clin Pharmacol (2009) 1.14
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther (2004) 1.12
Pilot study to assess the influence of an enhanced medication plan on patient knowledge at hospital discharge. Eur J Clin Pharmacol (2014) 1.10
Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther (2007) 1.09
Patients' beliefs about medicines in a primary care setting in Germany. J Eval Clin Pract (2010) 1.06
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos (2006) 1.06
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother (2011) 1.04
Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol (2009) 1.02
Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol (2011) 1.01
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother (2011) 0.99
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol (2003) 0.97
Steady-state pharmacokinetics and metabolism of voriconazole in patients. J Antimicrob Chemother (2013) 0.95
Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics (2011) 0.94
Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.94
Induction of multiple drug transporters by efavirenz. J Pharmacol Sci (2009) 0.93
7-Aminoactinomycin D for apoptosis staining in flow cytometry. Anal Biochem (2012) 0.93
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol (2004) 0.92
Prevention of intravenous drug incompatibilities in an intensive care unit. Am J Health Syst Pharm (2008) 0.92
Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol (2004) 0.92
Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol (2009) 0.92
Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother (2010) 0.91
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J (2013) 0.91
Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol (2004) 0.91
Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents (2013) 0.90
Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab Dispos (2005) 0.89
Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther (2003) 0.89
In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.87
Health care costs in the elderly in Germany: an analysis applying Andersen's behavioral model of health care utilization. BMC Health Serv Res (2014) 0.87
Can a feedback report and training session on medication counseling for general practitioners improve patient satisfaction with information on medicines? Patient Prefer Adherence (2012) 0.87
Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol (2010) 0.86
Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol (2013) 0.86
Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation. Br J Clin Pharmacol (2004) 0.86
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol (2012) 0.85
No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother (2010) 0.85
Regulation of biotransformation systems and ABC transporters by benznidazole in HepG2 cells: involvement of pregnane X-receptor. PLoS Negl Trop Dis (2012) 0.84
No difference in genotype frequencies of polymorphisms of the nitric oxide pathway between Caucasian normal and high tension glaucoma patients. Mol Vis (2012) 0.84
Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.84
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5. J Med Chem (2011) 0.84
Lack of evidence for association of high altitude pulmonary edema and polymorphisms of the NO pathway. High Alt Med Biol (2003) 0.83
Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet (2004) 0.83
Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos (2005) 0.83
In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol (2004) 0.83
Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. Br J Clin Pharmacol (2012) 0.81
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol (2007) 0.81
Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol (2011) 0.81
Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother (2010) 0.81
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemother Pharmacol (2014) 0.80
Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem Biol Interact (2010) 0.80
Characteristics of medication schedules used by elderly ambulatory patients. Eur J Clin Pharmacol (2015) 0.80
Daily honey consumption does not change CYP3A activity in humans. J Clin Pharmacol (2010) 0.80
Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro. Drug Metab Dispos (2012) 0.80
Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol (2010) 0.80
Cholesterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells. Biochem Biophys Res Commun (2004) 0.79
Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Alcohol Clin Exp Res (2012) 0.79
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol (2004) 0.79
NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics. Cell Tissue Res (2006) 0.79
P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine. Addict Biol (2003) 0.79
ATP-binding cassette transporters as pitfalls in selection of transgenic cells. Anal Biochem (2009) 0.78
In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins. J Pharm Pharmacol (2013) 0.78
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Biochem Pharmacol (2012) 0.78
Inappropriate crushing information on ward lists: cytotoxic drugs, capsules, and modified release formulations are gravely neglected. Eur J Clin Pharmacol (2014) 0.78
Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. Br J Clin Pharmacol (2013) 0.77
Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine. Biochem Biophys Res Commun (2004) 0.77
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck (2010) 0.77
Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. AIDS (2002) 0.77